Eledon Pharmaceuticals Inc [ELDN] stock is trading at $2.66, down -1.85%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELDN shares have lost -15.02% over the last week, with a monthly amount drifted -31.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on January 28, 2025, and set its price target to $9. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $25 on March 23, 2021.
Eledon Pharmaceuticals Inc [ELDN] stock has fluctuated between $2.38 and $5.54 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Eledon Pharmaceuticals Inc [NASDAQ: ELDN] shares were valued at $2.66 at the most recent close of the market. An investor can expect a potential return of 238.35% based on the average ELDN price forecast.
Analyzing the ELDN fundamentals
Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -403.54%, Pretax Profit Margin comes in at -96.96%, and Net Profit Margin reading is -99.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.25 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.62 points at the first support level, and at 2.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.72, and for the 2nd resistance point, it is at 2.79.
Ratios To Look Out For
For context, Eledon Pharmaceuticals Inc’s Current Ratio is 13.91. On the other hand, the Quick Ratio is 13.91, and the Cash Ratio is 0.92.
